Clinical Trial Update: A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating AC220 (quizartinib) in combination with induction and consolidation therapy for newly diagnosed acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Quizartinib (Quizartinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Leukemia, Myeloid, Acute | Phase 1 | Status: COMPLETED